Oncimmune Holdings Plc Sales growth to come from a number of directions

Oncimmune Holdings Plc (LON:ONC) is the topic of conversation when Dr Gary Waanders the Director of Healthcare Research at Zeus Capital caught up with DirectorsTalk. Gary talks us through the latest interim results, the company’s key strengths and explains what is going to drive top line growth in the next 2-3 years.

Gary is an experienced healthcare analyst having worked in the City since early 2001. He joined Zeus in January 2014 and is responsible for research coverage of all our Life Sciences corporate clients which include companies active in biotechnology, specialty pharmaceuticals, medical technology and clinical research services. He has worked on numerous IPOs and M&A mandates in the UK and Europe and has previously worked at Nomura Code Securities and KBC Peel Hunt. Prior to becoming an analyst, he managed an R&D group at a Canadian biotech company and before that he was a post-doctoral fellow at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland. His academic training includes an MBA from the University of Durham Business School and a PhD in Immunology from the Faculty of Medicine at Monash University (Australia) where he also obtained a BSc (Hons) in Immunology and Biochemistry.


Oncimmune Holdings Plc is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company’s first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers. EarlyCDT® tests for liver and ovarian cancer are in development.